Supplementary Materials for

2	
3	ATRIP deficiency impairs the replication stress response and manifests as
4	microcephaly primordial dwarfism and immunodeficiency.
5	Evi Duthoo ^{1,2,3} †, Elien Beyls ^{1,2,3} †, Lynn Backers ^{1,4,5} †, Thorkell Gudjónsson ⁶ , Peiquan Huang ⁶ , Leander
6	Jonckheere ^{7,8} , Sebastian Riemann ^{8,9} , Bram Parton ^{4,5} , Likun Du ¹⁰ , Veronique Debacker ^{1,2} , Marieke De Bruyne ^{4,5} ,
7	Levi Hoste ¹¹ , Ans Baeyens ¹² , Anne Vral ¹² , Eva Van Braeckel ^{7,8} , Jens Staal ^{13,14} , Geert Mortier ¹⁵ , Tessa Kerre ^{2,16} ,
8	Qiang Pan-Hammarström ¹⁰ , Claus Storgaard Sørensen ⁶ , Filomeen Haerynck ^{1,2,17} ‡*, Kathleen BM Claes ^{4,5} ‡*,
9	Simon J Tavernier ^{1,2,4,13,14} ‡
10	
11	Corresponding authors:
12	Filomeen Haerynck, Filomeen.Haerynck@UGent.be; Kathleen BM Claes, Kathleen.Claes@UGent.be
13	
15	
14	
15	
16	The file includes:
17	Case description
18	Supplementary Figures 1-8
19	Supplementary Tables 1-9

20 Case descriptions

21 Personally identifiable patient information was redacted in accordance with medRxiv requirements.

22 Supplementary Figures



24 Supplementary Figure 1.

23

25 a Photographs of patients F1Pt and F46.1 demonstrating facial similarities, including sloping forehead and beak-26 like nose. b Weight (Wght), height (Hgt), and head circumference (occipital frontal circumference; OFC) at birth 27 plotted as z-scores (SD from population mean for age and sex). Dashed line at -2SD indicates cut-off for normal 28 population distribution. ATRIP patients are denoted by red dots, ATR patients are denoted by blue dots. c 29 Electropherograms of genomic DNA extracted from blood for F1Pt and a healthy control (HC). Nucleotide 30 numbering is in accordance with ENST00000320211.1. Images represent results from 5 independent experiments. 31 d Population genetics: Highest SpliceAI Delta Score against gnomAD v4.0.0. allele frequency (AF) for splice 32 region variants in ATRIP (ENST00000320211.1). Splice region variants are defined as nucleotide changes within

33 the ± 20 base pairs (bp) flanking the exon. Black dots and blue cross signs represent heterozygous and homozygous 34 variants, respectively. More details regarding homozygous splice variants can be found in Supplementary Table 35 4. Red shaded dots represent ATRIP variants of interest (c.829+5G>T and c.829+2T>G). e Fragment analysis and size profiles of PCR-amplified cDNA extracted from fibroblasts for F1Pt and a HC. Arrows indicate the position 36 37 of forward and reverse primers used for PCR amplification. Percentages represent relative quantification of the 38 538bp wild type and 380bp mutant (r.7671_829del) fragment. Data are reflective of 2 independent experiments. f 39 Electropherograms of cDNA extracted from PHA blasts for F1Fa (father), F1Mo (mother), and a HC. Nucleotide 40 numbering is in accordance with ENST00000320211.1. Data are reflective of five independent experiments. g 41 Sashimi plot of targeted RNA-seq data generated in Integrative Genomics Viewer (IGV). Input RNA was extracted 42 from PHA blasts of F1Pt and a HC. Exon numbering is in accordance with ENST00000320211.1. h Fragment 43 analysis of PCR-amplified cDNA using two primer pairs (S1: E3-E5; S2: E5-E7, indicated by arrows) on 44 fibroblasts from F1Pt and a HC. Data is reflective of two independent experiments. i Real-time quantitative PCR 45 (RT-qPCR) analysis on fibroblasts of F1Pt and HCs (n = 3) of amplicon in exon 3-4 and exon 5-6. The relative expression to β -actin in a logarithmic scale is shown. Data from 2 independent experiments is shown. **j** Endogenous 46 protein expression of ATRIP and interaction partners in EBV immortalized lymphoblastoid cell lines (EBV-LCLs) 47 from F1Pt, F1Fa, and HCs (n = 3). B-tubulin was used as loading control. Western blot image is reflective of two 48 49 independent experiments. k Quantification in arbitrary units of digitized chemiluminescent signals from Fig. 1E 50 normalized to β -tubulin signal from the same lane. Graph depicts fold increase of normalized protein levels over

51 the mean of HCs (n = 3) of 4 immunoblots. Source data are provided as a Source Data file.



53 Supplementary Figure 2.

54 **a** Pie charts displaying the distribution of naïve T (CCR7⁺CD45RA⁺), T effector memory (CCR7⁻CD45RA⁻, T_{EM}),

55 T central memory (CCR7⁺CD45RA⁻, T_{CM}), and terminally differentiated T effector (CCR7⁻CD45RA⁺, T_{EMRA})

cells in CD8⁺ and CD4⁺ T cells of ATRIP patient (F1Pt) and healthy controls (HCs) (n = 6). **b** Percentages of T

57 and NK subsets in PBMCs of F1Pt and HCs (n = 6), based on manual gating of 25-parameter flow cytometry

58 (FCM) data. Mean and SEM are shown. **c** Percentages of B and innate subsets in PBMCs of F1Pt and HCs (n = 6), based on manual gating of 25-parameter FCM data. Mean and SEM are shown.

57 b), based on manual gating of 25-parameter FCW data. Weah and SEW are shown





61 Supplementary Figure 3.

a Dotplot depicting signature genes defining the UMAP clusters shown in Fig. 3a. b Circos plots showing the
 TRBV and *TRAV* pairing pattern of T cells of ATRIP patient (F1Pt) and healthy controls (HCs). c Frequency of

- 64 unique T cell clones in F1Pt and HCs. **d** Distribution of the CDR3 region lengths of TCR- α and TCR- β clones of
- 65 F1Pt and HCs T cells. e Circos plots demonstrating the IGH, IGK, and IGK pairing pattern of F1Pt and HCs B
- cells. **f** Frequency of unique B cell clones in F1Pt and HCs. **g** Distribution of the CDR3 region lengths of heavy
- 67 and light chain of F1Pt and HCs B cells.



69 Supplementary Figure 4.

68

a MSigDB hallmark gene sets differentially expressed in PBMCs from F1Pt compared to HCs (n = 3). Normalized
 Enrichment Score (NES) values of the gene sets are depicted. b Enrichment plots for two MSigDB hallmark gene
 sets differentially expressed in PBMCs from F1Pt compared to HCs (n = 3). The profile of the running Enrichment
 Score (ES) is depicted for both hallmark gene sets. c Heatmap displaying the top 20 enriched hallmark gene sets

74 (MSigDB) in T effector cells of F1Pt compared to HCs (n = 3). **d** Heatmap showing the top 20 enriched altered

- hallmark gene sets (MSigDB) in NK cells of F1Pt compared to HCs (n = 3). e Contour plot showing CD4⁺ T cell
- 76 maturation in HC and F1Pt. F1Pt (-) represents pre-treatment with anti-CD20 mAb (aCD20), F1Pt (+) represents
- post-treatment with anti-CD20. **f** Contour plot displaying CD8⁺ T cell maturation in HC and F1Pt. F1Pt (-)
- represents pre-treatment with anti-CD20, F1Pt (+) represents post-treatment with anti-CD20. **g** Frequencies of CD4⁺ T, CD8⁺ T, NK, and B cells in PBMCs from HCs (n = 18) and F1Pt pre- and post-treatment with anti-CD20.
- 80 Data represents one experiment, with each datapoint representing one biological replicate. Mean and SEM are
- shown. **h** ICOS, OX40, PD1, and CTLA4 expression on CD4⁺ T cells of HCs (n = 6) and F1Pt pre- and post-
- treatment with anti-CD20 mAb. Bar plots display median fluorescence (MFI). Mean and SEM are shown. Source
- 83 data are provided as a Source Data file.



Supplementary Figure 5.

86 a Representative immunofluorescence images of cells shown in Fig. 2a with DAPI and ATR staining. Fibroblasts from a healthy control (HC), ATRIP patient (F1Pt), and ATR patient (F02-98) were left untreated or exposed to 87 88 0.02 µg/ml Mitomycin C (MMC), 200 J/m² UV or 2 Gy IR. ATR was stained by immunofluorescence following 89 24h (MMC) or 3h (UV and IR) of treatment. Images are representative of three independent experiments. Scale 90 bars are 20 µm. b pATR and pCHK1 levels shown in Fig. 5b were quantified and represent three independent 91 experiments. Bar graph depicts pATR and pCHK1 levels post 200 J/m² UV treatment, expressed as a fold increase 92 over the mean levels observed in three healthy controls. Mean and SD are depicted. c yH2AX expression was 93 determined by flow cytometric analysis 3h following 200 J/m² UV exposure in EdU+ fibroblasts of HC and F1Pt. 94 Median fluorescence intensity (MFI) is annotated on the histogram. Data are reflective of one experiment. d 95 Immunoblotting of T1989-pATR and total ATR with and without lambda phosphatase (λ PPase) treatment on HC 96 fibroblasts, untreated or 3h after 200 J/m² UV exposure. GAPDH serves as a loading control. Source data are

97 provided as a Source Data file.



99 Supplementary Figure 6.

100a Cell cycle distributions of PHA blasts from healthy controls (HCs) and ATRIP patient (F1Pt). Cells were either101untreated or treated with $0.02 \,\mu$ g/ml Mitomycin C (MMC) and subsequently harvested at the timepoints indicated102on the schematics. Scatter dot plot depicts data from at least five independent experiments. Mean and SD are103shown. ns: not significant, *** p<0.001 (multiple paired t-tests). b Representative immunofluorescence images</td>

- 104 with DAPI, EdU, and RPA staining of data shown in Fig. 6d. HC and F1Pt fibroblasts were untreated or exposed
- to 1 mM hydroxyurea (HU) for 3h. Images are representative of three independent experiments. Scale bars are 20
- 106 μ m. **c** Flow cytometric (FCM) EdU pulse-labeling profiles of HC and F1Pt fibroblasts demonstrating the inhibiting
- 107 effect of HU treatment on replication progression. Cells were exposed to 1 mM HU for 3h and subsequently
- harvested. Data are representative of two experiment. d EdU pulse-chase analysis after exposure to 4 Gy IR in the
 absence or presence of 20 nM ATRi. HC and F1Pt PHA blasts were harvested after 9h. Bar plot (left) shows EdU+
- 110 cells present in G2/M phase after IR exposure, depicted as a fold change over the percentage observed in the mock
- 111 condition. Data represents 5 independent experiment. Mean and SD are shown. **p<0.01 (two-tailed paired t-test).
- Bar plot (right) shows percentages of EdU+ cells present in G0/G1, S, and G2/M phase. Data from one experiment
- 113 is shown. **e** FCM gating strategy of EdU pulse-chase kinetics presented in Fig. 6g and Supplementary Fig. 6d. **f**
- 114 Precursor frequency (PF) and proliferation index (PI) of CD8⁺ and CD4⁺ PHA blasts from HC and F1Pt. Cells
- 115 were labeled with CellTrace Violet (CTV) and subsequently cultured for 96h in the presence or absence of 0.02
- 116 µg/ml MMC. Data of at least two independent experiment is shown, with each datapoint representing one
- biological replicate. Mean and SD are shown. ns: not significant, *p<0.05, **p<0.01, **** p<0.0001 (multiple
- 118 paired t-tests). Source data are provided as a Source Data file.



120 Supplementary Figure 7.

a Representative immunofluorescence images with DAPI and yH2AX staining of data shown in Fig. 7A. yH2AX
 foci are shown in untreated fibroblasts from a control (HC), ATRIP patient (F1Pt), and ATR patient (F02-98).

- 123 Images are representative of three independent experiments. Scale bars are 20 µm. b Using the G0 and S
- micronucleus (MN) assay, micronuclei were scored in PHA blasts exposed to 0.5 Gy ionizing radiation (IR). Mean
 MN values of a reference HC group are indicated by dashed lines. Dotted lines correspond to the mean of HCs +
- 126 3SD and serve as a cut-off for sensitivity to IR. Data of two independent experiments is shown for F1Pt, in each
- experiment an internal control (IC) was included. One experiment was performed for the family members (F1Si,
- 128 F1Fa, F1Mo). **c**, **d** Fibroblasts from HC, F1Pt, and F02-98 were exposed to genotoxic inducers ($0.2 \mu g/ml$ MMC,
- 129 20 J/m² UV, or 10 Gy IR) in combination with a specific kinase inhibitor (2 µM DNA-PKi) (c) or only treated
- 130 with 20 nM ATRi, 10 µM ATMi, or 2 µM DNA-PKi (**d**). Cell death was monitored by live imaging up to 120h by
- 131 quantifying the number of cells stained with SYTOX Green. Represented cell death kinetic plots are reflective of
- 132 at least two independent experiments. **e**, **f** Corresponding proliferation curves of the data shown in Fig. 7g and h.
- 133 Fibroblasts from HC, F1Pt, and F02-98 were untreated or exposed to genotoxic inducers (0.2 µg/ml MMC, 20
- 134 J/m² UV, or 10 Gy IR) without (e) or with (f) specific kinase inhibitors (20 nM ATRi or 10 μM ATMi) as indicated.
- 135 Percentage of confluency was monitored by live imaging up to 120h. Data is representative of at least two
- 136 independent experiments. Source data are provided as a Source Data file.

a MCF10A



137

138 Supplementary Figure 8.

a Schematics of genome editing of the *ATR* and *ATRIP* allele (top). Blue lines represent the location of crRNAs,
 orange arrows depict the joint primers annealing to sequence outside the crRNA cutting regions, and red arrows

represent the primers annealing to depletion region, used for WT allele detection. The western blot verification of

142 mono-allelic cells is shown (bottom). Cells were seeded in 6 cm dish and $1 \mu g/ml$ doxycycline was added in the

143 culture medium 24 hours before cell lysis to induce the expression of cas9 protein. **b** Cell fitness of MCF10A

144 mono-allelic cells with frameshift mutations serving as internal control. Each variant has three independent

biological replicates. Mean and SEM are shown. *p<0.05, **p<0.01, ***<0.001 (two-tailed paired t-tests). Source

146 data are provided as a Source Data file.

148 Supplementary Tables

- 149 Supplementary Table 1. Clinical features of ATRIP patient (F1Pt). The clinical presentation is compatible with microcephaly primordial dwarfism (MPD).
- 150 *Personally identifiable patient information was redacted in accordance with medRxiv requirements.*

151 Supplementary Table 2. Scores indicating aberrant splicing as predicted by various *in silico* tools (GRCh38, hg38).

Prediction tool	g.48457421G>T, c.829+5G>T	g.48457418T>G, c.829+2T>G
SpliceAl Delta Score (donor loss)	0.71	0.73
Pangolin Delta Score (splice loss)	0.75	0.79
RF Score	0.874	0.926
ADA Score	0.99909	0.99997
MaxEntScan Difference	3.827	7.647
CADD/PHRED Score	23.5	33.0

GnomAD variant ID (GRCh38)	rsID (dbSNP)	HGVS nomenclature (NM_130384.3)	Allele frequency (gnomAD v4.0.0)	Number of homozygotes (gnomAD v4.0.0)	SpliceAl Delta Score (effect, location)	ClinVar (Accession)	Pangolin Delta Score (effect, location)
3-48464565-A-C	rs2242150	c.1975-17A>C	0.560807635	256364	0.01 (AG, -88bp)	Not reported	0.01 (gain, 17bp)
3-48464823-T-C	rs3135937	c.2056-8T>C	0.007480602	552	0.10 (AG, 40bp)	Benign (VCV001267070.6)	0.02 (loss, 8bp)
3-48464819-C-A	rs3135936	c.2056-12C>A	0.007435878	549	0.05 (AG, 44bp)	Benign (VCV001276028.5)	0.03 (loss, 12bp)
3-48450188-T-C	rs11922041	c.381+18T>C	0.001880775	45	0.00 (AL, -151bp)	Benign (VCV001621536.5)	0.00 (loss, -18bp)
3-48450019-T-A	rs182766845	c.248-18T>A	0.004657135	26	0.02 (AG, 2bp) 0.02 (AL, 18bp)	Benign (VCV001613091.5)	0.11 (loss, 18bp)
3-48464149-C-T	rs138467436	c.1974+17C>T	0.000717299	11	0.00 (DL, -17bp) 0.04 (DG, 119bp)	Benign (VCV001990326.1)	NA
3-48464815-A-AC	rs201468664	c.2056-9dup	0.001302093	2	0.05 (AG, 48bp)	Benign (VCV001987555.1)	0.04 (loss, 16bp)
3-48464678-C-T	NA	c.2055+16C>T	0.000001368	1	0.00 (DG, -16bp)	Not reported	0.00 (gain, -16bp)
3-48464821-CCTCT-C	rs754954019	c.2056-6_2056-3del	0.00031091	1	0.18 (AG, 46bp)	Likely benign (VCV002065669.1)	NA
3-48464822-CT-C	rs367546309	c.2056-8del	0.000039899	1	0.16 (AG, 41bp)	Likely benign (VCV000742744.4)	0.05 (loss, 1bp)
3-48465474-C-CT	rs765487326	c.2309-8dup	0.000013017	1	0.08 (AG, 15bp)	Not reported	0.02 (gain, 13bp)

153 Supplementary Table 3. Overview of homozygous *ATRIP* splice variants in gnomAD v4.0.0.

154 AG: acceptor gain; AL: acceptor loss; DG: donor gain; DL: donor loss; NA: not available

155 Supplementary Table 4. Considered alternative diagnoses and the associated genes for patient F1Pt. No other (likely) pathogenic variants were identified in patient F1Pt

using whole exome sequencing (WES) analyzing both SNVs and CNVs (MAF cut-off <0.02).

Disorder	Associated games
Seckel syndrome	ATR, RBBP8, CENPJ, CEP152, DNA2, TRAIP, CEP63, NIN, NSMCE2
MOPD type I/III	RNU4ATAC
MOPD type II	PCNT
Meier-Gorlin syndrome	ORC1, ORC4, ORC6, CDT1, CDC6, CDC45L, GMNN, MCM5
Silver-Russell syndrome	ICR1, IGF2, PLAG1, HMGA2
3M syndrome	CUL7, OBSL1, CCDC8
Cornelia de Lange syndrome	NIPBL, SMC1A, HDAC8, RAD21, SMC3, BRD4
Bloom syndrome	BLM
Fanconi anemia	MAD2L2, MAD2B, FANCV, UBE2T, HSPC150, FANCT, PHF9, FANCL, FANCD2, FANCD, FACD, FAD, FANCE, FACE, XRCC2, FANCU, SPGF50, POF17, XRCC9, FANCG, FANCC, FACC, FANCF, BRCA2, FANCD1, BROVCA2, GLM3, PNCA2, RAD51, RECA, MRMV2, FANCR, FANCI, KIAA1794, SLX4, BTBD12, MUS312, KIAA1784, KIAA1987, FANCP, ERCC4, XPF, FANCQ, XFEPS, PALB2, FANCN, PNCA3, BROVCA5, RFWD3, FANCW, FANCA, FACA, FA1, FA, FAA, BRCA1, PSCP, BROVCA1, PNCA4, FANCS, RAD51C, FANCO, BROVCA3, BRIP1, BACH1, FANCJ, FANCB, FAAP95, FAAP90, FLJ34064

158 Supplementary Table 5. Sequences of primers used for variant confirmation (gDNA), splice analysis (cDNA), and real-time qPCR (mRNA) analysis.

Primer sequence (5' \rightarrow 3')	Anneal site	Reference	Comment	
Variant confirmation (gDNA)				
Forward: <i>M13</i> -CTGACAAAGAATGGTAGACATATAATAG Reverse: <i>M13</i> -ATTGCTGATCACAGAAATTGG	Exon 5 + intron 5	ENST00000320211, GRCh38/hg38 (<i>ATRIP</i>)	universal M13 primers. Sequence of M13 forward and reverse tag is TGTAAAACGACGGCCAGT and CAGGAAACAGCTATGACC, respectively.	
Splice analysis (cDNA)				
Forward: M13-AAGATCACATTTTCTTCTTGAGCA Reverse: M13-CTGGGATCAAAGGCTGCTT	Exon 3 Exon 7	ENST00000320211, GRCh38/hg38 (<i>ATRIP)</i>	-	
Reverse: GTGGGGAAGGGACATGTTAG	Exon 5	ENST00000320211, GRCh38/hg38	Sanger sequencing primer	
Forward: GGAAAAACCCTTCTGTGGTT	Exon 5	(ATRIP)	Sanger sequencing primer	
Real-time qPCR analysis (mRNA)				
Hs.PT.58.46500972	Exon 3-4	NM 130384 (ATRIP)	Primer pair	
Hs.PT.58.15253191	Exon 5-6		Primer pair	
Housekeeping gene RT-qPCR (mRNA)				
Forward: CTGGAACGGTGAAGGTGACA	ACTB	<u>_</u>		
Reverse: AAGGGACTTCTTGTAACAATGCA	ACTB			

Antigen	Fluorochrome	Clone	Company
CD3	BUV395	UCHT1	BD
CD8	BUV496	RPA-T8	BD
CD278	BUV563	DX29	BD Optibuild
CCR7	BUV615	2-L1-A	BD
HLA-DR	BUV661	G46-6	BD
CD95	BUV737	563	BD Optibuild
CD4	BUV805	SK3	BD
CXCR3	BV421	G025H7	Biolegend
CXCR5	BV480	RF8B2	BD
CD16	BV570	3G8	Biolegend
CD152	BV605	BNI3	Biolegend
CD39	BV650	TU66	BD Horizon
CD25	BV711	BC96	Biolegend
CCR4	BV750	1G1	BD Optibuild
CD28	BV785	CD28.2	Biolegend
TCRg/d	FITC	B1	Biolegend
PD1	BB660-P	EH12.1	BD
CD56	BB790-P	NCAM16-2	BD
CD134	PerCP Cy5-5	ACT35	Biolegend
FoxP3	PE	206D	Biolegend
CCR6	PE-Dazzle594	G034E3	Biolegend
SA	PE-Cv5	206D	BD
CD27	PE-Cv7	O323	Biolegend
CD45RA	APC	HI100	Biolegend
Va7.2	AF700	3C10	Biolegend
CD161	APC-Fire750	HP-3G10	Biolegend
Va24Ja18	biotin	6B11	Thermofisher
CD24	BUV395	ML5	BD
CXCR3	BUV496	1C8	BD Optibuild
CCR7	BUV615	2-L1-A	BD
HLA-DR	BUV661	G46-6	BD
CD86	BUV737	2331 (FUN-1)	BD
CD3	BUV805	UCHT1	BD
CD1c	BV421	L161	Biolegend
CD185	BV480	RF8B2	BD
CD16	BV570	3G8	Biolegend
laD	BV605	IA6-2	Biolegend
CD11c	BV650	3.9	Biolegend
CD25	BV711	BC96	Biolegend
CD14	BV750	63D3	Biolegend
CD20	BV785	2H7	Biolegend
PD1	BB660	EH12.1	BD Horizon
CD169	BB515	7-239	BD Horizon
CD123	BB630	7G3	BD Horizon
CD94	PerCP-Cv5-5	18D3	Biolegend
CD21	PE	Bu32	Biolegend
CD64	PE-Dazzle594	10.1	Biolegend
IaM	PE-Cv5	G20-127	BD
CD19	PE-Cv7	HIB19	 Biolegend
CD141	AF647	M80	Biolegend
CD27	R718	M-T271	BD
CD38	APC-eFire750	HIT2	Biolegend
0000		1112	Diologona

160 Supplementary Table 6. Detailed overview of the monoclonal antibodies used for immunophenotyping.

Supplementary Table 7. Designed CRISPR RNAs (crRNAs) and PCR primers for generating the mono allelic cell lines used in CRISPR-SELECT^{TIME}.

Mono-allelic cell line	crRNAs	PCR Primers
ATR+/-	crRNA1: CACCTCTTCAATACACAGGC crRNA2: ATCTTTAATAAGTCTTGTAC	Primer for detecting WT allele: Forward: TGAACCTCACTGTCTTTTCCTT Reverse: AGTTTTAGAGCTGTGAACATCCT Joint Primer: Forward: TGAAGATGTGACCTCCCTCG Reverse: AGGGTTAAGGATGACATGAAGGA
ATRIP+ [≁]	crRNA1: TTACTCTTGAGAGCAAAGCA crRNA2: TACAGCCCAATAATGAAACC	Primer for detecting WT allele: Forward: TTGAGCTCAGCAGTTCCAGA Reverse: TCCAGTCCCTGCAGAGATTG Joint Primer: Forward: GAGGGTGAGGCACAAGA Reverse: GGGGAGCACGATGGACTGG

Variants	crRNAs	PCR Primers
ATR c.2022A>G	ATCCGGGCTAGTTGTGTTAG	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT TCCTTGAGTGGAGAACAGCAGT Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT ACCCTGCATACATAGCCAGACA
ATRIP c.829+5G>T	ATACATCAATAGATGACTAA	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT ACATGTCCCTTCCCCACCCCTG Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT TGTCCCCTCTGTGCCTTGTCAGA
ATRIP c.829+2T>G	ATACATCAATAGATGACTAA	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT ACATGTCCCTTCCCCACCCCTG Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT TGTCCCCTCTGTGCCTTGTCAGA
ATRIP c.2278C>T	GGGGTCAGCATGCTCATCCG	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT GCACGGCCTATCGCAGAAGGAC Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT ACCTCTGGAAGAAGCCATGGGGG
ATRIP c.248-14A>G	ATTTTTTACAGGTGATCATA	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT CTGCACTCCAACCTGGGTAACA Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT TGTGCCTGAAGTACCTCTAATTCGA
ATRIP c.2056-6_2056-3del	CGCTCTGACCACCTGAGAGA	Forward: ACACTCTTTCCCTACACGACGCTCTTCCGATCT AGGTGAGTGGGTAGGGGCCAAC Reverse: TGACTGGAGTTCAGACGTGTGCTCTTCCGATCT TCCGCACTGTCAGCCACTGTCT

Supplementary Table 8. Designed CRISPR RNAs (crRNAs) and PCR primers for variants analysis with CRISPR-SELECT^{TIME}.

Supplementary Table 9. Designed mutation (MUT) and wild-type (WT*) DNA repair templates for variants
 analysis with CRISPR-SELECT^{TIME}.

Variants	MUT repair template	WT* repair template
ATR c.2022A>G	CCTGCAGAGCTCCCATGAAGTAATCCGGGC TAGTTGTGTGAGTGGGTTTTTTATCTTATTGC AGCAGCAGAATTCTTGTAACAGAGTTCC	CCTGCAGAGCTCCCATGAAGTAATCCGGGC TAGTTGTGTGAGCGGATTTTTTATCTTATTGC AGCAGCAGAATTCTTGTAACAGAGTTCC
ATRIP c.829+5G>T	CAGACGGAGTCAGGATACAAGCCTCTGGTG GGCAGAGAGGGTAATTCCATTACTCATCTAT TGATGTATAACAAGCTACCCAAATATGTG	CAGACGGAGTCAGGATACAAGCCTCTGGTG GGCAGAGAAGGTAAGTCCATTACTCATCTAT TGATGTATAACAAGCTACCCAAATATGTG
ATRIP c.829+2T>G	TGCCAGACGGAGTCAGGATACAAGCCTCTG GTGGGCAGAGAGGGGGAAGTCCATTACTCAT CTATTGATGTATAACAAGCTACCCAAATAT	TGCCAGACGGAGTCAGGATACAAGCCTCTG GTGGGCAGAGAAGGTAAGTCCATTACTCATC TATTGATGTATAACAAGCTACCCAAATAT
ATRIP c.2278C>T	TGCATCAGTTTGACCAGGTGATGCCGGGGG TCAGCATGCTCATTTGAGGGCTTCCTGATGT GACGGACTGTGAAGGTAAGCCTGCCAGAG	TGCATCAGTTTGACCAGGTGATGCCGGGGG TCAGCATGCTCATTCGTGGGCTTCCTGATGT GACGGACTGTGAAGGTAAGCCTGCCAGAG
ATRIP c.248-14A>G	TCTGGCAAAAGTGGGAAAATATTGGGTCCTG AAATGTATATGGAGCTATTTTTTACAGGTGAT CACAAGGTCCACAGATTATTAGATGGC	TCTGGCAAAAGTGGGAAAATATTGGGTCCTG AAATGTATATGGAACTATTTTTTACAGGTGAC CACAAGGTCCACAGATTATTAGATGGC
ATRIP c.2056-6_2056-3del	TAGGGTGCAGGCCATGGTGGCACCAGGCCT CAGTCTGCACCCCCCCTCAGGTGGTCAGAG CGCTCACGGTGATGTTGCACAGACAGTGGC	GTGCAGGCCATGGTGGCACCAGGCCTCAGT CTGCACCCCCCCTCTCTCAGGTCGTCAGAG CGCTCACGGTGATGTTGCACAGACAGTGGC